Publications by authors named "Russell B Poe"

Article Synopsis
  • - AST-004 is a small molecule that targets adenosine receptors and shows promise for protecting the brain after strokes and injuries, aiming to assess its safety and how it's processed in the body during a phase I clinical trial on healthy individuals.
  • - The study involved giving varying doses of AST-004 to different groups of participants and then analyzing its levels in blood, cerebrospinal fluid (CSF), and urine; no serious side effects were observed, though headaches were reported by some.
  • - Findings indicated that AST-004 is safe at higher concentrations than previously effective in animal studies and that it reaches highest levels in CSF an hour after infusion, suggesting it may be suitable for further testing in treating strokes and brain injuries.
View Article and Find Full Text PDF

A linear route has been used to prepare ()-methanocarba-nucleoside derivatives, which serve as purine receptor ligands having a pre-established, receptor-preferred conformation. To introduce this rigid ribose substitute, a Mitsunobu reaction of a [3.1.

View Article and Find Full Text PDF

The A adenosine receptor (AAR) is a target for pain, ischemia, and inflammatory disease therapy. Among the ligand tools available are selective agonists and antagonists, including radioligands, but most high-affinity non-nucleoside antagonists are limited in selectivity to primate species. We have explored the structure-activity relationship of a previously reported AAR antagonist DPTN (-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]nicotinamide) for radiolabeling, including 3-halo derivatives (3-iodo, MRS7907), and characterized as a high -affinity radioligand [H]MRS7799.

View Article and Find Full Text PDF

Background And Purpose: Treatment with A1R/A3R (adenosine A1 and A3 receptor) agonists in rodent models of acute ischemic stroke results in significantly reduced lesion volume, indicating activation of adenosine A1R or A3R is cerebroprotective. However, dosing and timing required for cerebroprotection has yet to be established, and whether adenosine A1R/A3R activation will lead to cerebroprotection in a gyrencephalic species has yet to be determined.

Methods: The current study used clinical study intervention timelines in a nonhuman primate model of transient, 4-hour middle cerebral artery occlusion to investigate a potential cerebroprotective effect of the dual adenosine A1R/A3R agonist AST-004.

View Article and Find Full Text PDF

Some Arctic estuaries serve as substrate rubbing sites for beluga whales (Delphinapterus leucas) in the summer, representing a specialized resource for the species. Understanding how environmental variation affects the species' behavior is essential to management of these habitats in coming years as the climate changes. Spatiotemporal and environmental variables were recorded for behavioral observations, during which focal groups of whales in an estuary were video-recorded for enumeration and behavioral analysis.

View Article and Find Full Text PDF

The assessment of provenance of heparin is becoming a major concern for the pharmaceutical industry and its regulatory bodies. Batch-specific [carbon (δ(13) C), nitrogen (δ(15) N), oxygen (δ(18) O), sulfur (δ(34) S), and hydrogen (δD)] stable isotopic compositions of five different animal-derived heparins were performed. Measurements readily allowed their differentiation into groups and/or subgroups based on their isotopic provenance.

View Article and Find Full Text PDF